Research Article
Long-Term Effect of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Injections in Choroidal Neovascularization Secondary to Angioid Streaks
Table 3
Central macular thickness variation by groups until 48 months (primary outcome).
| | CMT variation | 12 months (n = 25) | 24 months (n = 28) | 36 months (n = 25) | 48 months (n = 22) |
| | Decrease> − 50 μm | 7 (28.0%) | 8 (28.6%) | 7 (28.0%) | 8 (36.4%) | | Between −50 and + 50 μm | 15 (60.0%) | 17 (60.7%) | 15 (60.0%) | 12 (54.5%) | | Increase > + 50 μm | 3 (12.0%) | 3 (10.7%) | 3 (12.0%) | 2 (9.1%) |
|
|
